Home » Stocks » RSLS

ReShape Lifesciences Inc. (RSLS)

Stock Price: $6.50 USD -0.79 (-10.84%)
Updated Feb 23, 2021 3:43 PM EST - Market closed
Market Cap 33.52M
Revenue (ttm) 12.14M
Net Income (ttm) -38.15M
Shares Out 6.97M
EPS (ttm) -5.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 23
Last Price $6.50
Previous Close $7.29
Change ($) -0.79
Change (%) -10.84%
Day's Open 7.00
Day's Range 6.50 - 7.15
Day's Volume 3,117
52-Week Range 1.51 - 11.5

News

Hide News
  • All
  • Videos
  • Press Releases
Seeking Alpha - 1 year ago

ReShape Lifesciences' (RSLS) CEO Bart Bandy on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

ReShape Lifesciences Inc. (RSLS) CEO Bart Bandy on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

ReShape Lifesciences Inc. (RSLS) CEO Bart Bandy on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

ReShape Lifesciences Inc.'s (RSLS) CEO Dan Gladney on Q4 2018 Results - Earnings Call Transcript

About RSLS

ReShape Lifesciences, a medical device company, focuses on the design, development, and commercialization of technology to treat obesity and metabolic diseases. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in morbidly obe... [Read more...]

Industry
Medical Devices
IPO Date
Nov 15, 2007
CEO
Barton Bandy
Employees
38
Stock Exchange
OTCMKTS
Ticker Symbol
RSLS
Full Company Profile

Financial Performance

In 2019, RSLS's revenue was $15.09 million, an increase of 2,385.83% compared to the previous year's $607,000. Losses were -$74.21 million, -8.56% less than in 2018.

Financial Statements